{"classes":[{"categories":[{"measurements":[{"comment":"PFS is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"30.5"},{"comment":"PFS is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"19.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"Median time to progression (months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Values here are estimated (from a Weibull model) as the medians were not met.","dispersionType":"95% Confidence Interval","groups":[{"description":"Vandetanib (300 mg daily)","id":"OG000","title":"Vandetanib 300 mg"},{"description":"Placebo daily","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent.","title":"Progression-Free Survival(PFS)","type":"PRIMARY","unitOfMeasure":"Months"}